Dermatology
Plaque Psoriasis Conference Series
Conference Reporter® Podcast: Long-term Disease Control in Plaque Psoriasis With IL-23–Targeted Therapies
Systemic treatment options for patients with moderate to severe plaque psoriasis are continuing to grow, with longer-term data helping clinicians assess the durability of skin clearance and safety over time. In today’s podcast, Diego Ruiz Dasilva, MD, FAAD, discusses IL-23–targeted injectable and oral therapies and long-term disease control in plaque psoriasis, based on data presented at the 2026 Fall Clinical Dermatology Conference.
Following these presentations, featured expert Diego Ruiz Dasilva, MD, FAAD, was interviewed by Conference Reporter Associate Editor-in-Chief Rick Davis, MS, RPh. Clinical perspectives from Dr Ruiz Dasilva on these findings are presented here.
Alexis A, Rodriguez AO, Yadav G, et al. Visible cohort A: guselkumab skin clearance and patient-oriented outcomes across skin and joint symptoms through week 100 in participants with moderate-to-severe plaque psoriasis across all skin tones. Poster presented at: 2026 Fall Clinical Dermatology Conference; October 8-11, 2026; Las Vegas, NV.
Angsana J, Hill C, Chen E, et al. Durability of systemic and skin pharmacodynamic responses with icotrokinra in moderate-to-severe plaque psoriasis: phase 3 ICONIC-LEAD week 52 results. Poster presented at: 2026 Fall Clinical Dermatology Conference; October 8-11, 2026; Las Vegas, NV.
Armstrong AW. Destination: clearer waters. A legacy of charting long-term data for adult patients with moderate to severe plaque psoriasis or active psoriatic arthritis. Session presented at: 2026 Fall Clinical Dermatology Conference; October 8-11, 2026; Las Vegas, NV.
Bissonnette R, Soung J, Hebert AA, et al. Oral icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med. 2025;393(18):1784-1795. doi:10.1056/NEJMoa2504187
Bissonnette R, Soung J, Pink AE, et al. Durability of response to icotrokinra in adults and adolescents with moderate-to-severe plaque psoriasis: 2-year ICONIC-LEAD findings. Poster presented at: 2026 Fall Clinical Dermatology Conference; October 8-11, 2026; Las Vegas, NV.
Stein Gold L, Armstrong AW, Soung J, et al. Durability of response to icotrokinra in adults with moderate-to-severe plaque psoriasis: 1-year results from the phase III, placebo- and active comparator-controlled ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials. Br J Dermatol. 2026;195(4):600. doi:10.1093/bjd/ljag264
This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the 2026 Fall Clinical Dermatology Conference.
